Overview

The Effects of Lipoic Acid on Glycaemic Control in Type 2 Diabetes

Status:
Unknown status
Trial end date:
2011-01-01
Target enrollment:
0
Participant gender:
All
Summary
Hypothesis: that lipoic acid supplements taken orally will improve control of blood sugar levels in people with type 2 diabetes. This study will recruit 18 people with type 2 diabetes, whose diabetes is currently managed on oral agents. Each subject will then either take placebo for 12 weeks followed by lipoic acid for 12 weeks, or lipoic acid followed by placebo. A blood test for overall diabetes control will be taken at the start and end of each 12 week period, and the change in control will be compared for lipoic acid vs placebo.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of Edinburgh
Collaborator:
NHS Lothian
Treatments:
Thioctic Acid
Criteria
Inclusion Criteria:

- Type 2 diabetes

- Age > 18 years

- Capable of giving informed consent

- Treated with oral antidiabetic agents (not insulin)

- HbA1c 7.0 - 8.5% at last measurement (must be within 6 months of study)

- Most recent HbA1c within 1% of all measurements within preceding year

- Prepared to self-test blood glucose on a regular basis

- Prepared to use contraception during study if of child-bearing potential

Exclusion Criteria:

- Unstable cardiac disease (NYHA class III or IV heart failure, or unstable angina or
myocardial infarction within last three months)

- Significant renal or hepatic impairment (creatinine>170 micromol/L, alanine
transaminase or alkaline phosphatase > 3x upper limit of normal)

- Other medical condition or treatment likely to affect glycaemic control

- Previous history of significant hypoglycaemia

- Pregnancy

- Involvement in other clinical trial in last three months

- Known or suspected sensitivity to trial products